http://www.medigus.com/modules/mod_image_show_gk4/cache/banners.medigus-home-slide-nov-2014-1gk-is-90.jpg http://www.medigus.com/modules/mod_image_show_gk4/cache/banners.medigus-home-slide-nov-2014-3gk-is-90.jpg http://www.medigus.com/modules/mod_image_show_gk4/cache/home_slides.medigus-home-slide-1gk-is-90.jpg http://www.medigus.com/modules/mod_image_show_gk4/cache/sages-2015-homegk-is-90.jpg

Text

MUSE™ SYSTEM - GERD Relief in Sight

GERD is caused by abnormal regurgitation of fluids from the stomach into the esophagus.

The MUSE™ innovative system offers incisionless treatment of Gastroesophageal Reflux Disease (GERD) by performing an anterior fundoplication in lieu of current surgical procedures, without opening the abdominal cavity.

The MUSE™ System is FDA cleared, CE marked and manufactured under ISO13485:2003.

READ MORE

Medigus is leading the transition from invasive gastric surgery procedures to less invasive, patient-friendly techniques through the development of minimally invasive endoscopic devices and procedures. The company's revolutionary MUSE™ System enables endoscopists to treat gastroesophageal reflux disease (GERD), a chronic disease with increasing global prevalence, by performing a fundoplication procedure through the mouth. Unlike current fundoplication procedures, the MUSE™ System does not require abdominal incisions, which may result in shorter post-procedure recovery. The MUSE™ System (previously known as SRS™ System for transoral fundoplication) has received FDA clearance and CE mark. Medigus is traded on the TASE (Tel Aviv Stock Exchange).

GERD RELIEF IN SIGHT

MINIMALLY INVASIVE MEDICAL PROCEDURES

TRANSORAL FUNDOPLICATION FOR GERD

MUSE™ SYSTEM - GERD Relief in Sight

News & Events